• Bile Acid Metabolism Subtypes and Immune Markers in Colorect

  2026-08-03

  Feng et al. present an integrative transcriptomic analysis linking bile acid metabolism to immune dysfunction in colorectal cancer. Their identification of CLCA1, UGT2A3, and ZG16 as downregulated markers associated with poor prognosis and altered immune infiltration provides a novel molecular subtyping framework with potential impact on prognosis and immunotherapy response.

• Axon Trafficking Regulates TIA1 Aggregation in Neurons

  2026-08-03

  This study uncovers a critical mechanism by which the adaptor protein ANXA7 mediates the retrograde transport of TIA1-containing ribonucleoprotein complexes (RNPs) in neuronal axons. Disruption of this trafficking pathway leads to pathological TIA1 aggregation, implicating axonal transport in neurodegeneration and offering new experimental strategies for RNA granule studies.

• Caspase-3 Fluorometric Assay Kit: Illuminating Apoptosis Pat

  2026-08-02

  Explore the Caspase-3 Fluorometric Assay Kit’s advanced role in dissecting apoptosis and ferroptosis crosstalk. This article delivers a scientific deep dive into cysteine-dependent aspartate-directed protease activity measurement, with unique insights from the latest research.

• ALDH2 Inhibition Triggers Synthetic Lethality in APC-Deficie

  2026-08-01

  A recent study reveals that inhibiting ALDH2 with Disulfiram induces synthetic lethality in APC-deficient colorectal cancer cells through ROS-mediated ASK1/JNK pathway activation. This work provides a mechanistic basis for targeting vulnerable genetic backgrounds in CRC and informs new therapeutic strategies.

• RG108: Precision DNA Methyltransferase Inhibitor for Epigene

  2026-07-31

  RG108 is a potent DNA methyltransferase inhibitor that enables non-covalent, reversible modulation of epigenetic gene regulation. It demonstrates high in vitro efficacy with an IC50 of 600 nM and is widely used to reactivate silenced tumor suppressor genes in cancer research. RG108's distinct solubility, storage, and application properties make it a reliable choice for experimental workflows.

• Ertapenem Sodium Salt: Applied Workflows in Antibacterial Re

  2026-07-31

  Ertapenem sodium salt offers robust, reproducible solutions for profiling both Gram-positive and Gram-negative bacteria, especially in resistance modeling. This guide translates the latest resistance transmission insights into hands-on workflow enhancements and troubleshooting tactics for advanced microbiology labs.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Applied Research

  2026-07-30

  10058-F4 uniquely blocks c-Myc-Max interaction, enabling precise modulation of oncogenic transcription in both cancer and stem cell assays. This guide delivers data-driven workflows, troubleshooting strategies, and real-world insights for optimizing apoptosis and differentiation studies using APExBIO’s validated c-Myc-Max dimerization inhibitor.

• ARCA Cy5 EGFP mRNA (5-moUTP): Reliable mRNA Delivery Benchma

  2026-07-30

  ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009) offers rigorous, reproducible solutions for mRNA localization and translation efficiency assays in mammalian cells. This evidence-based guide explores how its 5-methoxyuridine modifications and dual fluorescence labeling streamline workflow, enhance sensitivity, and suppress innate immune activation, making it a benchmark tool for transfection efficiency and cytotoxicity studies.

• CDK4-Dependent 4E-BP1 Phosphorylation: Chemoproteomic Insigh

  2026-07-29

  Mitchell et al. developed a chemoproteomic pipeline enabling phosphosite-specific mapping of kinase-substrate interactions, revealing CDK4 as a direct regulator of the translational repressor 4E-BP1. This work illuminates how CDK4 influences mTORC1-inhibitor resistance and c-Myc translation in breast cancer, informing future therapeutic strategies.

• ECL Chemiluminescent Substrate Detection Kit: Sensitivity &

  2026-07-29

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) enables high-sensitivity antibody detection with extended signal duration. This kit, from APExBIO, supports low-picogram protein quantification in western blot assays and offers robust, low-background chemiluminescence for clear imaging results.

• I-BET151 (GSK1210151A): Benchmark BET Bromodomain Inhibitor

  2026-07-28

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor targeting BRD2, BRD3, and BRD4, widely used in cancer biology research. Its efficacy in inducing cell cycle arrest and apoptosis is dose-dependent and reproducible, with APExBIO providing a validated formulation. This article details mechanistic insights, evidence, and workflow integration for advanced research.

• Mitochondria-Targeted AIE Photosensitizer: Synthesis and Eva

  2026-07-28

  This study introduces a concise synthetic route for a novel mitochondrion-targeted tetraphenylethylene-based photosensitizer with aggregation-induced emission (AIE) properties. The work demonstrates enhanced singlet oxygen generation, phototoxicity, and biocompatibility, highlighting the compound’s promise for photodynamic therapy and inspiring new approaches for cell viability assays in cancer research.

• Integrated In Vivo and Cell Screening Accelerates PDA Drug D

  2026-07-27

  This study introduces a dual cell and in vivo screening platform leveraging Rgs16::GFP expression to rapidly evaluate chemotherapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Notably, Trichostatin A (TSA), an HDAC inhibitor, enhances drug efficacy and provides mechanistic insight into epigenetic regulation in PDA progression.

• 3-Methyladenine in Translational Autophagy Research: Mechani

  2026-07-27

  This thought-leadership article explores how 3-Methyladenine (3-MA), a selective class III PI3K inhibitor, advances mechanistic autophagy research and translational oncology, with a particular focus on recent discoveries in uveal melanoma. Integrating mechanistic insights, evidence-based protocol guidance, and a strategic competitive landscape, the article provides actionable perspectives for translational researchers aiming to harness autophagy modulation in cancer and beyond.

• Toremifene in Breast Cancer: Two Decades of Clinical Insight

  2026-07-26

  This review synthesizes two decades of clinical data on toremifene, a selective estrogen receptor modulator (SERM), in the context of breast cancer therapy. It highlights the comparative efficacy, safety, and evolving role of toremifene versus standard therapies, emphasizing implications for estrogen receptor-positive disease and personalized medicine.

16283 records 1/1086 page Next 12345 下5页 Last page